Tango Therapeutics Inc (TNGX)

Currency in USD
24.39
+0.33(+1.37%)
Real-time Data·
Trading near 52-week High
TNGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.8025.13
52 wk Range
1.0325.13
Key Statistics
Prev. Close
24.06
Open
23.94
Day's Range
23.8-25.13
52 wk Range
1.03-25.13
Volume
2.73M
Average Vol. (3m)
3.29M
1-Year Change
1,673.8182%
Book Value / Share
2.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TNGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.30
Downside
-8.57%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Tango Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics Inc SWOT Analysis


Market Potential
With a $13 price target from Barclays, Tango's success in upcoming trials could attract partnerships or acquisition interest from major pharmaceutical companies
Financial Outlook
Despite negative EPS forecasts, Tango boasts a strong balance sheet with extended cash runway into 2027, demonstrating effective resource management
Clinical Milestones
Anticipate crucial Phase 1 expansion trial results for pancreatic and lung cancers, with potential to significantly impact stock performance and market position
Precision Oncology
Tango Therapeutics pioneers innovative cancer treatments, focusing on PRMT5 and CoREST complex inhibitors to exploit genetic vulnerabilities in cancer cells
Read full SWOT analysis

Compare TNGX to Peers and Sector

Metrics to compare
TNGX
Peers
Sector
Relationship
P/E Ratio
−33.8x−10.1x−0.5x
PEG Ratio
−1.27−0.020.00
Price / Book
9.9x5.0x2.6x
Price / LTM Sales
55.1x13.0x3.2x
Upside (Analyst Target)
−14.8%75.5%47.6%
Fair Value Upside
Unlock−5.7%6.1%Unlock

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.30
(-8.57% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy28.00+14.29%19.00MaintainApr 13, 2026
Canaccord
Buy30.00+22.45%-New CoverageApr 02, 2026
B.Riley
Buy21.00-14.29%14.00MaintainMar 27, 2026
Mizuho
Buy20.00-18.37%19.00MaintainMar 11, 2026
Stifel
Buy24.00-2.04%15.00MaintainMar 09, 2026

Earnings

Latest Release
Mar 05, 2026
EPS / Forecast
-0.29 / -0.32
Revenue / Forecast
-- / 500.4K
EPS Revisions
Last 90 days

TNGX Income Statement

People Also Watch

64.215
AXTI
-4.58%
141.730
AAOI
-3.18%
7.48
IBRX
-1.58%
18.110
AMPX
+1.23%

FAQ

What Is the Tango Therapeutics (TNGX) Stock Price Today?

The Tango Therapeutics stock price today is 24.39 USD.

What Stock Exchange Does Tango Therapeutics Trade On?

Tango Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Tango Therapeutics?

The stock symbol for Tango Therapeutics is "TNGX."

What Is the Tango Therapeutics Market Cap?

As of today, Tango Therapeutics market cap is 3.46B USD.

What Is Tango Therapeutics's Earnings Per Share (TTM)?

The Tango Therapeutics EPS (TTM) is -0.87.

When Is the Next Tango Therapeutics Earnings Date?

Tango Therapeutics will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is TNGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Tango Therapeutics Stock Split?

Tango Therapeutics has split 0 times.

How Many Employees Does Tango Therapeutics Have?

Tango Therapeutics has 137 employees.

What is the current trading status of Tango Therapeutics (TNGX)?

As of Apr 15, 2026, Tango Therapeutics (TNGX) is trading at a price of 24.39 USD, with a previous close of 24.06 USD. The stock has fluctuated within a day range of 23.80 USD to 25.13 USD, while its 52-week range spans from 1.03 USD to 25.13 USD.

What Is Tango Therapeutics (TNGX) Price Target According to Analysts?

The average 12-month price target for Tango Therapeutics is 22.30 USD, with a high estimate of 30 USD and a low estimate of 16 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an -8.57% Downside potential.

What Is the TNGX Premarket Price?

TNGX's last pre-market stock price is 24.14 USD. The pre-market share volume is 1,640.00, and the stock has decreased by 0.08, or 0.33%.

What Is the TNGX After Hours Price?

TNGX's last after hours stock price is 24.74 USD, the stock has decreased by 0.68, or 2.83%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.